1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth (Q48627896)

13 February 2018

title

1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth (English)

1 reference

13 February 2018

4

Valérie Rigau

1 reference

13 February 2018

author name string

Catherine Gozé

1

1 reference

13 February 2018

Charlotte Bezzina

2

1 reference

13 February 2018

Eric Gozé

3

1 reference

13 February 2018

Thierry Maudelonde

5

1 reference

13 February 2018

Luc Bauchet

6

1 reference

13 February 2018

Hugues Duffau

7

1 reference

13 February 2018

publication date

6 March 2012

1 reference

13 February 2018

Journal of Neuro-Oncology

published in

1 reference

13 February 2018

volume

108

1 reference

13 February 2018

issue

1

1 reference

13 February 2018

page(s)

69-75

1 reference

13 February 2018

An integrated genomic analysis of human glioblastoma multiforme

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Molecular Classification of Low-Grade Diffuse Gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Continuous growth of mean tumor diameter in a subset of grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Prognostic stratification of patients with anaplastic gliomas according to genetic profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Dynamic history of low-grade gliomas before and after temozolomide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

A simple salting out procedure for extracting DNA from human nucleated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

p53 protein accumulation and gene mutations in human glioma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Glioma IDH1 mutation patterns off the beaten track.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0831-6

Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas

21 January 2018

1 reference

12 December 2020

Comparative study of p53 gene and protein alterations in human astrocytic tumors

1 reference

12 December 2020

Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects

1 reference

12 December 2020

Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.

1 reference

12 December 2020

Robust Regression: Asymptotics, Conjectures and Monte Carlo

1 reference

19 June 2022

https://opencitations.net/index/coci/api/v1/citations/10.1214/AOS/1176342503

Identifiers

DOI

10.1007/S11060-012-0831-6

1 reference

13 February 2018

1 reference

13 February 2018